Vor Biopharma Inc. is an innovative biopharmaceutical company based in Cambridge, Massachusetts, specializing in engineered hematopoietic stem cell (eHSC) therapies designed to revolutionize cancer treatment. Leveraging proprietary technology platforms, Vor is committed to developing targeted therapies that optimize patient outcomes while aspiring for durable responses and enhanced survival rates. As a leader in the evolving oncology landscape, Vor's strategic focus on cell therapies reflects its potential for significant advancements in cancer therapeutics, making it a compelling opportunity for institutional investors seeking to support cutting-edge medical solutions. Show more

Location: 100 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA, UNITED STATES, 02140, Cambridge, MA, 02140, USA | Website: https://www.vorbio.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

532M

52 Wk Range

$2.62 - $65.80

Previous Close

$13.74

Open

$13.70

Volume

467,346

Day Range

$13.30 - $14.10

Enterprise Value

365.4M

Cash

160.5M

Avg Qtr Burn

-53.66M

Insider Ownership

3.56%

Institutional Own.

43.85%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Telitacicept Details Myasthenia gravis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Telitacicept Details Sjogren's Disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Telitacicept Details IgA neuropathy (IgAN)	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VCAR33 (ALLO) Details Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trem-cel (VOR33) + VCAR33 Details Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trem-cel (VOR33) + Mylotarg (VBP101) Details Acute myeloid leukemia, Myelodysplastic syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.

We track quarterly 13F filings for some of the largest biotech hedge funds here.